NCT00318942

Brief Summary

Background: Two recent systematic reviews of the literature and meta-analyses have suggested that colloids administration might be deleterious in critically ill patients. Objective: To compare the effects on hospital mortality of crystalloids and colloids when given for fluid resuscitation in critically ill patients. Setting: Adult intensive care units (ICUs) in several European countries. Study design: A multinational, randomised, controlled trial performed on two parallel groups. Intervention: Any type of crystalloids (control group) versus any type of colloids (including albumin). Patients: All patients above the legal age of consent and hospitalised in an intensive care unit, who need fluid resuscitation (according to the physician). Pregnant women, moribund patients, brain dead patients, and patients who have a known allergy to colloids or severe head injury or major burns (\> 20% of body surface) or dehydration will not be included. Primary endpoint: 28-day mortality. Hypothesis: Assuming a hospital mortality rate of 20% in the crystalloids group, a 0.05 type I error, 3010 patients are needed to show a difference between the 2 groups of 5% with a 90% probability (two-sided test).

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,857

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Feb 2003

Longer than P75 for phase_3

Geographic Reach
5 countries

67 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2003

Completed
2.6 years until next milestone

First Submitted

Initial submission to the registry

September 2, 2005

Completed
8 months until next milestone

First Posted

Study publicly available on registry

April 27, 2006

Completed
6.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2012

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2012

Completed
Last Updated

July 1, 2014

Status Verified

June 1, 2014

Enrollment Period

9.5 years

First QC Date

September 2, 2005

Last Update Submit

June 29, 2014

Conditions

Keywords

SepsisMultiple TraumaHypovolemic Shock

Outcome Measures

Primary Outcomes (1)

  • 28-day mortality

    Day 28

Secondary Outcomes (5)

  • ICU and hospital mortality rates

    Day 90

  • Number of days free of mechanical ventilation (MV), vasopressors, renal replacement therapy, and organ system failure

    Day 90

  • Difference in the area under the curve (AUC) of mean arterial pressure (MAP) from HO to H24, in weight gain, in PaO2/FiO2 ratio, chest X-ray score

    Day 2

  • Frequency of adverse events

    day 90

  • Length of stay (LOS)

    Day 90

Study Arms (2)

1

ACTIVE COMPARATOR

Crystalloids, any type of Crystalloids including isotonic or hypertonic saline, Ringer Lactates either modified or not

Drug: Crystalloids

2

EXPERIMENTAL

Colloids, including albumin, gelatines, starch any other synthetic colloids

Drug: Colloids

Interventions

Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay

1

Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay

2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females, above the legal age of consent
  • Hospitalized in intensive care unit
  • Need fluid resuscitation (according to the physician in charge of the patient)

You may not qualify if:

  • Patients who have one or more of the following items:
  • Known allergy to gelatins, albumin or starch
  • Coagulation disorders (haemophilia, Willebrand disease, etc.)
  • Chronic renal failure on permanent dialysis
  • Severe hepatic failure
  • Burns \> 20 % of body surface
  • Pregnancy
  • Volume replacement: As a part of anaesthesia, for anaphylactic shock, or for dehydration
  • Brain death
  • Advance directive of withholding or withdrawal of life-sustaining treatments
  • Any other investigational drugs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (67)

Hôpital Erasme

Brussels, Belgium

Location

CHU de Sherbrooke-Höpital Fleurimont

Fleurimont, Canada

Location

Hôpital Charles LeMoyne

Québec, Canada

Location

CH d'Angers

Angers, France

Location

Centre Hospitalier d'Annecy

Annecy, France

Location

CH Joseph Imbert

Arles, France

Location

CH d'Arpajon

Arpajon, France

Location

CHG de Bastia

Bastia, France

Location

Hôpital Avicenne

Bobigny, France

Location

CH Pellegrin Tripode

Bordeaux, France

Location

Hôpital Cavale Blanche

Brest, France

Location

Chg Briancon

Briançon, France

Location

HIA Percy

Clamart, France

Location

Hôpital A. Beclere

Clamart, France

Location

Hôpital Corbeil Essonnes

Corbeil-Essonnes, France

Location

Hôpital Henri Mondor

Créteil, France

Location

Hôpital Général

Dijon, France

Location

CH Dourdan

Dourdan, France

Location

Centre Hospitalier d'Etampes

Étampes, France

Location

Hôpital de FREYMING-MERLEBACH

Freyming-Merlebach, France

Location

Hôpital Raymond Poincaré

Garches, 92380, France

Location

CHR

La Roche-sur-Yon, France

Location

Hôpital A. Mignot

Le Chesnay, France

Location

CHU Liege

Le Liège, France

Location

Hôpital Claude Huriez

Lille, France

Location

CH Dupuytren

Limoges, France

Location

Centre Régional Léon Bernard

Lyon, France

Location

Hôpital Louis Pradel

Lyon, France

Location

CH MEAUX

Meaux, France

Location

Hôpital Saint Eloi

Montpellier, France

Location

Centre Hospitalier de Mulhouse

Mulhouse, France

Location

Hôpital Central

Nancy, 54000, France

Location

Hôpital Central NANCY

Nancy, France

Location

Polyclinique de Gentilly

Nancy, France

Location

CHRG d'Orléans

Orléans, France

Location

HEGP

Paris, France

Location

Hôpital Bichat Claude Bernard

Paris, France

Location

Hôpital Bicêtre

Paris, France

Location

Hôpital la Pitié Salpétrière

Paris, France

Location

Hôpital Lariboisière

Paris, France

Location

Hôpital Saint Louis

Paris, France

Location

Hôpital TENON

Paris, France

Location

Hôtel Dieu

Paris, France

Location

CHU de Bordeaux

Pessac, France

Location

Chu Lyon Sud

Pierre-Bénite, France

Location

CHI Poissy

Poissy, France

Location

CHU de Poitiers

Poitiers, France

Location

Centre Hospitalier R. Dubos

Pontoise, France

Location

CH Claude Galien

Quincy-sous-Sénart, France

Location

Chu Reims

Reims, France

Location

CHU Rennes

Rennes, France

Location

CH Victor Provo

Roubaix, France

Location

Hôpital Charles Nicolle

Rouen, France

Location

Centre Cardiologique du Nord

Saint-Denis, 93000, France

Location

CHI Saint Germain en Laye

Saint-Germain-en-Laye, France

Location

CH Mémorial SAINT LO

Saint-Lô, France

Location

CHG de SOISSONS

Soissons, France

Location

Hôpital Civil

Strasbourg, France

Location

Hôpital Hautepierre

Strasbourg, France

Location

CHR Bel Air

Thionville, France

Location

CHU Toulouse

Toulouse, France

Location

CHG Valence

Valence, France

Location

CHU Brabois Nancy

Vandœuvre-lès-Nancy, France

Location

Hôpital T Sfar

Mahdia, Tunisia

Location

Chu Bourguiba

Monastir, Tunisia

Location

Hôpital A Mami

Tunis, Tunisia

Location

Homerton University Hospital

London, United Kingdom

Location

Related Publications (2)

  • Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declere AD, Preiser JC, Outin H, Troche G, Charpentier C, Trouillet JL, Kimmoun A, Forceville X, Darmon M, Lesur O, Reignier J, Abroug F, Berger P, Clec'h C, Cousson J, Thibault L, Chevret S; CRISTAL Investigators. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA. 2013 Nov 6;310(17):1809-17. doi: 10.1001/jama.2013.280502.

  • Heming N, Elatrous S, Jaber S, Dumenil AS, Cousson J, Forceville X, Kimmoun A, Trouillet JL, Fichet J, Anguel N, Darmon M, Martin C, Chevret S, Annane D; CRISTAL Investigators. Haemodynamic response to crystalloids or colloids in shock: an exploratory subgroup analysis of a randomised controlled trial. BMJ Open. 2017 Oct 6;7(10):e016736. doi: 10.1136/bmjopen-2017-016736.

MeSH Terms

Conditions

Critical IllnessSepsisMultiple TraumaShock

Interventions

Crystalloid SolutionsColloids

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsInfectionsSystemic Inflammatory Response SyndromeInflammationWounds and Injuries

Intervention Hierarchy (Ancestors)

Isotonic SolutionsSolutionsPharmaceutical PreparationsComplex MixturesDosage Forms

Study Officials

  • Djillali Annane, MD, PhD

    Assistance Publique Hôpitaux de Paris - University of Versailles

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor in medicine

Study Record Dates

First Submitted

September 2, 2005

First Posted

April 27, 2006

Study Start

February 1, 2003

Primary Completion

August 1, 2012

Study Completion

November 1, 2012

Last Updated

July 1, 2014

Record last verified: 2014-06

Locations